<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00882557</url>
  </required_header>
  <id_info>
    <org_study_id>3009-027</org_study_id>
    <secondary_id>DAP-RENID-08-06</secondary_id>
    <nct_id>NCT00882557</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Daptomycin Given During Dialysis and After Dialysis</brief_title>
  <official_title>A Prospective, Randomized, Crossover-design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether daptomycin at a higher dose given during
      the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after
      a dialysis session.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2009</start_date>
  <completion_date type="Actual">July 17, 2009</completion_date>
  <primary_completion_date type="Actual">July 17, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Area Under the Curve From Time 0 to Infinity</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion, mid-infusion, and end of the infusion; at 1, 2, 4, 6, 9, 24, and 48 hours after the end of the infusion; and just prior to the next hemodialysis session (i.e., 68 hours post-infusion)</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to infinity for daptomycin doses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Adverse Events</measure>
    <time_frame>Up to 9 days after the last dose of study drug administration (Day 13 to Day 17 for those dosed on Day 8 and Day 20 to Day 24 for those dosed on Day 15).</time_frame>
    <description>Safety was monitored throughout the study, including observation and reports of AEs as well as changes in physical findings, vital signs, ECGs, and laboratory tests.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion, mid-infusion, and end of the infusion; at 1, 2, 4, 6, 9, 24, and 48 hours after the end of the infusion; and just prior to the next hemodialysis session (i.e., 68 hours post-infusion)</time_frame>
    <description>Maximum plasma concentration over the entire sampling phase directly obtained from the experimental plasma concentration time data, without interpolation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Maximum Concentration</measure>
    <time_frame>Up to 68 hours post dose</time_frame>
    <description>Sampling time at which maximum plasma concentration occurred, obtained directly from the experimental plasma concentration time data, without interpolation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Half-life</measure>
    <time_frame>Up to 68 hours post dose</time_frame>
    <description>Apparent terminal half-life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clearance of Daptomycin</measure>
    <time_frame>Up to 68 hours post dose</time_frame>
    <description>Plasma clearance is dose (µg) divided by area under the concentration versus time curve from time 0 to last quantifiable concentration time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of Distribution</measure>
    <time_frame>Up to 68 hours post dose</time_frame>
    <description>Volume of distribution at steady state (mL) calculated as the product of clearance and mean residence time.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>End-stage Renal Disease</condition>
  <condition>Renal Failure Chronic Requiring Hemodialysis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 mg/kg of daptomycin administered during the last 30 minutes of a hemodialysis session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post dialysis dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daptomycin</intervention_name>
    <description>intradialytic: 9 mg/kg during the last 30 minutes of dialysis</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Cubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daptomycin</intervention_name>
    <description>6 mg/kg administered after a hemodialysis session</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Cubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent prior to any study-related procedure not part of normal
             medical care;

          -  Male or female ≥ 18 years of age;

          -  If female of childbearing potential; willing to practice reliable birth control
             measures during study treatment and for at least 28 days after study completion, not
             lactating or pregnant, and has a documented negative pregnancy test result within 24
             hours prior to study medication administration;

          -  End-stage renal disease on stable (for at least 2 weeks) hemodialysis regimen, three
             times weekly using high-flux membranes;

          -  Functioning hemodialysis access (for example, graft or fistula);

          -  Considered to be in appropriate health for study entry by the Investigator (for
             example, no acute, debilitating medical problems) and appropriate candidate for
             completing study treatment;

          -  If taking concomitant medications, subject must be on a relatively stable dose for at
             least two weeks prior to study drug administration.

        Exclusion Criteria:

          -  Received an investigational drug (including experimental biologic agents) within 30
             days of study drug administration;

          -  Has received any dose of daptomycin within 7 days prior to study drug administration;

          -  Known to be allergic or intolerant to daptomycin;

          -  Evidence of active ongoing infection;

          -  Known human immunodeficiency virus (HIV) infection with CD4 count ≤ 200 cells/mm3;

          -  Active illicit drug use or alcohol abuse;

          -  Myocardial infarction within last 6 months;

          -  Subject with a history of muscular disease (for example, polymyositis, muscular
             dystrophy);

          -  Subject with a history of neurological disease (for example, Guillain Barré, multiple
             sclerosis), except stroke &gt; 6 months prior to study entry;

          -  Intramuscular injection within 7 days of study drug administration;

          -  Body mass index (BMI) ≤ 18.5 or ≥ 40 kg/m2 (BMI = weight [kg]/height [m2]);

          -  WBC ≥ 12, 000 cells/mm3 or ≤ 2500 cells/ mm3;

          -  Neutropenic subject with absolute neutrophil count ≤ 500 cells/mm3;

          -  Baseline CPK values ≥ 3X ULN (upper limit of normal);

          -  Alanine aminotransferase (ALT) &gt; 5XULN;

          -  Aspartate aminotransferase (AST) &gt; 5XULN;

          -  Hemoglobin ≤ 9 gm/dL;

          -  Is considered unlikely to comply with study procedures or to return for scheduled
             post-treatment evaluations;

          -  History of rhabdomyolysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alistair Wheeler, MD, MFPM</last_name>
    <role>Study Director</role>
    <affiliation>Cubist Pharmaceuticals LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2009</study_first_submitted>
  <study_first_submitted_qc>April 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2009</study_first_posted>
  <results_first_submitted>July 19, 2011</results_first_submitted>
  <results_first_submitted_qc>September 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 25, 2011</results_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End-stage renal disease</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>chronic renal failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects evaluated for entry within 7 days prior to randomization, washout period of 7-14 days between doses, subjects began Day 1 on Friday of Monday/Wednesday/Friday or Saturday of Tuesday/Thursday/Saturday hemodialysis schedule</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence BA</title>
          <description>All subjects received 1 dose of daptomycin 6 mg/kg after hemodialysis (Regimen B) and 1 dose of daptomycin 9 mg/kg during the last 30 minutes of hemodialysis (Regimen A).</description>
        </group>
        <group group_id="P2">
          <title>Sequence AB</title>
          <description>All subjects received 1 dose of daptomycin 9 mg/kg during the last 30 minutes of hemodialysis (Regimen A) and 1 dose of daptomycin 6 mg/kg after hemodialysis (Regimen B).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trouble with Vein Access</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence BA</title>
          <description>All subjects received 1 dose of daptomycin 6 mg/kg after hemodialysis (Regimen B) and 1 dose of daptomycin 9 mg/kg during the last 30 minutes of hemodialysis (Regimen A).</description>
        </group>
        <group group_id="B2">
          <title>Sequence AB</title>
          <description>All subjects received 1 dose of daptomycin 9 mg/kg during the last 30 minutes of hemodialysis (Regimen A) and 1 dose of daptomycin 6 mg/kg after hemodialysis (Regimen B).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Safety population (1 patient included in the overall number of baseline participants in the &quot;Sequence AB&quot; arm was randomized but not treated)</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.6" spread="13.19"/>
                    <measurement group_id="B2" value="55.3" spread="6.05"/>
                    <measurement group_id="B3" value="53.3" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Safety population (1 patient included in the overall number of baseline participants in the &quot;Sequence AB&quot; arm was randomized but not treated)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Area Under the Curve From Time 0 to Infinity</title>
        <description>Area under the plasma concentration versus time curve from time 0 to infinity for daptomycin doses</description>
        <time_frame>Within 30 minutes prior to the start of the infusion, mid-infusion, and end of the infusion; at 1, 2, 4, 6, 9, 24, and 48 hours after the end of the infusion; and just prior to the next hemodialysis session (i.e., 68 hours post-infusion)</time_frame>
        <population>The primary endpoints are measured on the PK population, defined as all subjects who received both the 6 mg/kg dose and 9 mg/kg dose</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg After Hemodialysis (Regimen B)</title>
            <description>Daptomycin (6 mg/kg IV) after hemodialysis using high-flux membranes</description>
          </group>
          <group group_id="O2">
            <title>9 mg/kg During Hemodialysis (Regimen A)</title>
            <description>Daptomycin (9 mg/kg IV) during the last 30 minutes of hemodialysis using high-flux membrane</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Area Under the Curve From Time 0 to Infinity</title>
          <description>Area under the plasma concentration versus time curve from time 0 to infinity for daptomycin doses</description>
          <population>The primary endpoints are measured on the PK population, defined as all subjects who received both the 6 mg/kg dose and 9 mg/kg dose</population>
          <units>hr*ug/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1692" lower_limit="962" upper_limit="2524"/>
                    <measurement group_id="O2" value="2708" lower_limit="1719" upper_limit="4010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum Plasma Concentration</title>
        <description>Maximum plasma concentration over the entire sampling phase directly obtained from the experimental plasma concentration time data, without interpolation.</description>
        <time_frame>Within 30 minutes prior to the start of the infusion, mid-infusion, and end of the infusion; at 1, 2, 4, 6, 9, 24, and 48 hours after the end of the infusion; and just prior to the next hemodialysis session (i.e., 68 hours post-infusion)</time_frame>
        <population>PK Population - defined as all subjects who received both doses of daptomycin</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg After Hemodialysis (Regimen B)</title>
            <description>Daptomycin (6 mg/kg IV) after hemodialysis using high-flux membranes</description>
          </group>
          <group group_id="O2">
            <title>9 mg/kg During Hemodialysis (Regimen A)</title>
            <description>Daptomycin (9 mg/kg IV) during the last 30 minutes of hemodialysis using high-flux membrane</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration</title>
          <description>Maximum plasma concentration over the entire sampling phase directly obtained from the experimental plasma concentration time data, without interpolation.</description>
          <population>PK Population - defined as all subjects who received both doses of daptomycin</population>
          <units>ug/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="35.8" upper_limit="104"/>
                    <measurement group_id="O2" value="100" lower_limit="56.5" upper_limit="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Maximum Concentration</title>
        <description>Sampling time at which maximum plasma concentration occurred, obtained directly from the experimental plasma concentration time data, without interpolation.</description>
        <time_frame>Up to 68 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg After Hemodialysis (Regimen B)</title>
            <description>Daptomycin (6 mg/kg IV) after hemodialysis using high-flux membranes</description>
          </group>
          <group group_id="O2">
            <title>9 mg/kg During Hemodialysis (Regimen A)</title>
            <description>Daptomycin (9 mg/kg IV) during the last 30 minutes of hemodialysis using high-flux membrane</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration</title>
          <description>Sampling time at which maximum plasma concentration occurred, obtained directly from the experimental plasma concentration time data, without interpolation.</description>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.50" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Half-life</title>
        <description>Apparent terminal half-life.</description>
        <time_frame>Up to 68 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg After Hemodialysis (Regimen B)</title>
            <description>Daptomycin (6 mg/kg IV) after hemodialysis using high-flux membranes</description>
          </group>
          <group group_id="O2">
            <title>9 mg/kg During Hemodialysis (Regimen A)</title>
            <description>Daptomycin (9 mg/kg IV) during the last 30 minutes of hemodialysis using high-flux membrane</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life</title>
          <description>Apparent terminal half-life.</description>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" lower_limit="19.7" upper_limit="38.1"/>
                    <measurement group_id="O2" value="31.1" lower_limit="21.9" upper_limit="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clearance of Daptomycin</title>
        <description>Plasma clearance is dose (µg) divided by area under the concentration versus time curve from time 0 to last quantifiable concentration time.</description>
        <time_frame>Up to 68 hours post dose</time_frame>
        <population>PK Population - defined as all subjects who received both doses of daptomycin</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg After Hemodialysis (Regimen B)</title>
            <description>Daptomycin (6 mg/kg IV) after hemodialysis using high-flux membranes</description>
          </group>
          <group group_id="O2">
            <title>9 mg/kg During Hemodialysis (Regimen A)</title>
            <description>Daptomycin (9 mg/kg IV) during the last 30 minutes of hemodialysis using high-flux membrane</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of Daptomycin</title>
          <description>Plasma clearance is dose (µg) divided by area under the concentration versus time curve from time 0 to last quantifiable concentration time.</description>
          <population>PK Population - defined as all subjects who received both doses of daptomycin</population>
          <units>mL/hr/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" lower_limit="2.38" upper_limit="6.23"/>
                    <measurement group_id="O2" value="3.32" lower_limit="2.24" upper_limit="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Volume of Distribution</title>
        <description>Volume of distribution at steady state (mL) calculated as the product of clearance and mean residence time.</description>
        <time_frame>Up to 68 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg After Hemodialysis (Regimen B)</title>
            <description>Daptomycin (6 mg/kg IV) after hemodialysis using high-flux membranes</description>
          </group>
          <group group_id="O2">
            <title>9 mg/kg During Hemodialysis (Regimen A)</title>
            <description>Daptomycin (9 mg/kg IV) during the last 30 minutes of hemodialysis using high-flux membrane</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution</title>
          <description>Volume of distribution at steady state (mL) calculated as the product of clearance and mean residence time.</description>
          <units>mL/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" lower_limit="107" upper_limit="221"/>
                    <measurement group_id="O2" value="145" lower_limit="115" upper_limit="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Adverse Events</title>
        <description>Safety was monitored throughout the study, including observation and reports of AEs as well as changes in physical findings, vital signs, ECGs, and laboratory tests.</description>
        <time_frame>Up to 9 days after the last dose of study drug administration (Day 13 to Day 17 for those dosed on Day 8 and Day 20 to Day 24 for those dosed on Day 15).</time_frame>
        <population>Safety population, defined as all subjects who received at least one dose of daptomycin</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg After Hemodialysis (Regimen B)</title>
            <description>Daptomycin (6 mg/kg IV) after hemodialysis using high-flux membranes</description>
          </group>
          <group group_id="O2">
            <title>9 mg/kg During Hemodialysis (Regimen A)</title>
            <description>Daptomycin (9 mg/kg IV) during the last 30 minutes of hemodialysis using high-flux membrane</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Adverse Events</title>
          <description>Safety was monitored throughout the study, including observation and reports of AEs as well as changes in physical findings, vital signs, ECGs, and laboratory tests.</description>
          <population>Safety population, defined as all subjects who received at least one dose of daptomycin</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 9 days after the last dose of study drug administration (Day 13 to Day 17 for those dosed on Day 8 and Day 20 to Day 24 for those dosed on Day 15).</time_frame>
      <desc>Safety was monitored throughout the study, including observation and reports of AEs as well as changes in physical findings, vital signs, ECGs, and laboratory tests.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sequence BA</title>
          <description>All subjects received 1 dose of daptomycin 6 mg/kg after hemodialysis (Regimen B) and 1 dose of daptomycin 9 mg/kg during the last 30 minutes of hemodialysis (Regimen A).</description>
        </group>
        <group group_id="E2">
          <title>Sequence AB</title>
          <description>All subjects received 1 dose of daptomycin 9 mg/kg during the last 30 minutes of hemodialysis (Regimen A) and 1 dose of daptomycin 6 mg/kg after hemodialysis (Regimen B).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first publication is initiated by Cubist. If First Publication not published within 1 year of Study conclusion or termination, Investigator has right to publish and disclose the Data. Prior to any submission for publication, presentation, or communication of results or information arising from the Study, Investigator shall provide Cubist at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ed Campanaro/Vice President, Clinical Operations</name_or_title>
      <organization>Cubist Pharmaceuticals, Inc.</organization>
      <phone>781-860-8318</phone>
      <email>ed.campanaro@cubist.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

